Victory Capital Management Inc. raised its position in Audentes Therapeutics Inc (NASDAQ:BOLD) by 2.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 880,601 shares of the biotechnology company’s stock after purchasing an additional 18,040 shares during the period. Victory Capital Management Inc.’s holdings in Audentes Therapeutics were worth $34,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. BB Biotech AG acquired a new position in Audentes Therapeutics in the 4th quarter valued at $16,404,000. Dimensional Fund Advisors LP bought a new stake in shares of Audentes Therapeutics during the 3rd quarter valued at $6,708,000. Assenagon Asset Management S.A. bought a new stake in shares of Audentes Therapeutics during the 4th quarter valued at $1,539,000. Artal Group S.A. lifted its position in shares of Audentes Therapeutics by 140.0% during the 4th quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock valued at $12,792,000 after acquiring an additional 350,000 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. bought a new stake in shares of Audentes Therapeutics during the 1st quarter valued at $264,000. 97.81% of the stock is currently owned by hedge funds and other institutional investors.
Shares of BOLD stock traded down $0.07 on Friday, hitting $38.93. 4,082 shares of the company’s stock were exchanged, compared to its average volume of 593,055. Audentes Therapeutics Inc has a 12 month low of $17.95 and a 12 month high of $46.18. The company has a market cap of $1.69 billion, a P/E ratio of -11.46 and a beta of 1.85.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.23). During the same period last year, the company posted ($0.74) earnings per share. On average, analysts anticipate that Audentes Therapeutics Inc will post -4.48 EPS for the current year.
In related news, Director Louis G. Lange sold 20,000 shares of the company’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $36.00, for a total transaction of $720,000.00. Following the completion of the sale, the director now directly owns 306,099 shares in the company, valued at approximately $11,019,564. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $30.06, for a total value of $300,600.00. Following the sale, the vice president now owns 28,236 shares of the company’s stock, valued at $848,774.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,000 shares of company stock valued at $2,020,400. 5.30% of the stock is owned by corporate insiders.
A number of analysts have recently weighed in on BOLD shares. BidaskClub upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, February 23rd. ValuEngine upgraded Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. HC Wainwright reiterated a “buy” rating and set a $44.00 target price (up from $33.00) on shares of Audentes Therapeutics in a research report on Monday, March 18th. Finally, Mizuho reiterated a “buy” rating and set a $45.00 target price on shares of Audentes Therapeutics in a research report on Friday, February 1st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. Audentes Therapeutics has a consensus rating of “Buy” and a consensus price target of $39.92.
Audentes Therapeutics Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Story: Purposes and Functions of the Federal Reserve
Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics Inc (NASDAQ:BOLD).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.